Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04153188 · ClinicalTrials.gov registry record · Phase 4
Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
A Phase 4 study of Erythematotelangiectatic Rosacea, sponsored by Candela Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 2
- Study locations
NCT04153188: Completed Phase 4 study of Erythematotelangiectatic Rosacea, sponsored by Candela Corporation.
NCT04153188 is a Phase 4 study of Erythematotelangiectatic Rosacea that has completed, run by Candela Corporation. The registered enrollment target is 34 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04153188, a Phase 4 study of Erythematotelangiectatic Rosacea, has completed, sponsored by Candela Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will compare treatment outcome with pulsed dye laser, when used used as an adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream alone, for patients with moderate or severe erythematotelangiectatic rosacea.
Primary Outcome
CEA was graded by the investigator according to 5-point scale (0=Clear to 4=Severe) for each patient at the 6-month post-baseline visits. A higher score indicates worse outcome. The outcomes presented here are the mean CEA calculated for the 6-month post-baseline visit of each arm.
Conditions Studied
Interventions
- DEVICE The Vbeam® Prima System
- DRUG Oxymetazoline HCL 1% Cream
Study Locations (2)
North Carolina
- Dermatology, Laser & Vein Specialists of the Carolinas - Charlotte
Texas
- Dermatology & Laser Surgery Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 4 |
What the finished NCT04153188 record still lists
NCT04153188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Erythematotelangiectatic Rosacea appearing as the primary indexed condition, and to 2 interventions - of which The Vbeam® Prima System is the first listed.
NCT04153188 reports a single indexed study location in North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT04153188 about?
NCT04153188 is a clinical study titled "Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea". This study will compare treatment outcome with pulsed dye laser, when used used as an adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream alone, for patients with moderate or severe erythematotelangiectatic rosacea.
What is the current status of trial NCT04153188?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2019-01-15. Estimated completion is 2021-01-05.
What conditions does trial NCT04153188 study?
This clinical trial studies the following conditions: Erythematotelangiectatic Rosacea.
What interventions are being tested in trial NCT04153188?
The interventions under investigation include: The Vbeam® Prima System (DEVICE), Oxymetazoline HCL 1% Cream (DRUG).
Who is sponsoring clinical trial NCT04153188?
This trial is sponsored by Candela Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04153188 being conducted?
This trial has 2 study locations across North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erythematotelangiectatic Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04153188's enrollment target sits among peer trials
34 1520th of 2000 higher than 473 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI